JPMorgan Starts Hemab Therapeutics Holdings (COAG) at Overweight

October 15, 2026 2:55 AM EDT Send to a Friend
JPMorgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Overweight rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login